Compare DGICA & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICA | LENZ |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.0M | 609.5M |
| IPO Year | N/A | 2021 |
| Metric | DGICA | LENZ |
|---|---|---|
| Price | $17.20 | $9.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $19.00 | ★ $45.60 |
| AVG Volume (30 Days) | 107.3K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | $2.26 | $51.35 |
| Revenue Next Year | N/A | $198.33 |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.43 | $8.25 |
| 52 Week High | $21.06 | $50.19 |
| Indicator | DGICA | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 40.28 |
| Support Level | $16.52 | $8.25 |
| Resistance Level | $17.48 | $12.70 |
| Average True Range (ATR) | 0.30 | 0.74 |
| MACD | 0.08 | 0.15 |
| Stochastic Oscillator | 50.58 | 52.93 |
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.